

Strócol


Citicoline Tablets



Reliving Memories

What is Strocol?

Strocol contains citicoline (citidine-5'-diphosphocholine) which is an endogenous nucleotide naturally found in the body, where it is an essential intermediate in the synthesis of the phosphatidylcholine, the major phospholipid of the cell membranes.^{1,2,3,5,6,8&11}




How does Strocol work?

- Reduces ischemic injury in the CNS by preserving membrane phospholipids, chiefly **phosphatidylcholine**.^{1,2,6&7}
- Promotes rapid repair of injured cell surface and mitochondrial membranes and maintenance of **cell integrity** and bioenergetics capacity.³
- Downregulates phospholipases to avoid the production of free fatty acids and avert apoptotic and necrotic death.^{1,2,3,5,7&8}
- In brain trauma patients, facilitates **memory rehabilitation** by restoring blood flow to the lesion site.⁷
- In Alzheimer's disease, improves **cognitive function** by serving as an acetylcholine precursor.⁷
- In Parkinson's disease, stimulates the release of dopamine neurotransmitters in the brain and can be beneficial for **treatment improvement**.^{1,3&7}
- Repairs damage to optic nerve and improves **visual acuity**.^{7,11&15}
- Improves **attention** in adolescents by increasing dopamine synthesis.^{3&16}



Literature Review

A trial lasting for 6 months in 172 patients with first-ever ischemic stroke showed that **citicoline** prevented cognitive decline after stroke. Significant reduction in cognitive impairment was seen in the domains of attention, temporal orientation, and executive functions.¹⁴



A randomized, double-blind, placebo-controlled, parallel group designed study with 95 elderly subjects showed that citicoline therapy improved verbal memory functioning and can be effective in treating age-related cognitive decline.⁹

A randomized, double-blind, placebo-controlled, three-arm designed study with 75 adolescents showed that citicoline therapy enhances motor and attentional abilities and decreases impulsivity (performance on the Finger Tap Test and Ruff 2&7 Speed task after supplementation improved ($p < 0.05$)).¹⁶



Why Strocol?

- Strocol is a **well-tolerated** supplement with great bioavailability, low toxicity and few side effects.^{3,6,7,9 & 11}
- Provides both **neuroprotection** and **neurorepair**.^{2&3}
- Increases the probability of recovery after moderate to severe **stroke**.^{1,2&9}
- Improves recovery in patients with traumatic **brain injury**.⁹
- Can be used by patients with poststroke **vascular cognitive impairment**.^{4&11}
- Improves **memory** and behavioral outcomes in **elderly**.⁷
- Can be used by patients with cognitive and treatment disorders such as **Alzheimer's** and **Parkinson's** disease.⁷
- Has beneficial effects as an **adjuvant therapy** in patients with Parkinson's disease.¹⁷
- Beneficial for patients with **amblyopia** and **glaucoma**.^{7,11&15}
- Can be used by **adolescents** with disorders involving poor attention such as ADHD.¹⁶



Abbreviated Product Information

Strocol

Citicoline, 500 mg tablets and 250 mg tablets

Other ingredients: Polyvinylpyrrolidone, Magnesium stearate, Colloidal silicon dioxide, Croscarmellose sodium.

Indication: Stroke recovery, vascular cognitive impairment like memory loss, Alzheimer's disease, Parkinson's disease, memory and behavioral function in elderly, glaucoma, amblyopia.

Recommended Dosage: 1 tablet per day.

Side effects: no serious adverse effects have been reported to date. But side effects may include dizziness and gastrointestinal problems like nausea.

Pregnancy & Lactation: Since there is no evidence related to taking Strocol[®] in pregnancy and breast feeding, consult your doctor before taking this product.

Precaution: In case of Parkinson's disease please consult your doctor for dose adjustment before taking it.

Strocol is a product of **Ashbal Chemi Co.**

1. Clinical Interventions in Aging 2006; 3,247-351.

2. Brain Sci. 2013;3.

3. Reviews in Neurological diseases 2008;vol 5, NO.4.

4. Cerebrovasc Dis 2013; 35:146-154.

5. Neurology 1997;49,671.

6. Journal of Stroke and Cerebrovascular Diseases 2014; 23, 1764-1769.

7. Alternative Medicine Review 2004;vol 9.

8. Stroke 1999;2593-2597.

9. Arch Neurol 1996;vol 53.

10. The Journal of Nutrition 2021;2153-2160.

11. Journal of Clinical Psychopharmacology 2007; vol27, no 5.

12. Journal of Neurochemistry 2002;80,12-23.

13. Journal of Neuroscience Research 2002;70,133-139.

14. Stroke 2011; 42:S40-S43.

15. European Journal of Neurology 2008;15:465-474.

16. Journal of attention disorders. 2019 Jan;23(2):121-34.

17. Clinical therapeutics. 2021 Jan 1;43(1):e19-31.